Session Program

ICSA 2009 Applied Statistics Symposium Program Schedule - June 22, Monday

Date	Time	Room	Session Title	Organizer	Chair	Speakers	Affiliation	Titles
Monday	8:30 a.m. - 10:10 a.m.	Grand Ball Room	Keynote Address	ICSA 2009 Applied Statistical	George Tiao, University of Chicago	Wing H. Wong	Stanford University	Some statistical issues in the analysis of next generation sequence data
22-Jun-09	10:10 a.m. - 10:30 a.m.	Ballroom Foyer	Break					
	10:30 a.m. - 12:10 p.m.	Cottonwood - 2nf Fl	#1. Special Invited Session by Statistics in Biosciences	Xihong Lin, Harvard University and Gordon Lan, Johnson & Johnson	Gordon Lan, Johnson & Johnson	1. James Hung 2. Gordan Lan	1. FDA 2. Johnson & Johnson	1. Recent Advances in Clinical Trial Design 2. Practical problems in group sequential design of clinical trials
		Aspen Room	#2. Statistical Innovations in Tailored Therapeutics	Ming-Dauh Wang, Eli Lilly and Company	Yongming Qu, Eli Lilly and Company	1. Wei Shen 2. Peggy Wong 3. Sue-Jane Wang	1. Lilly USA, LLC 2. Merck Research Laboratories 3. Office of Translational Sciences, CDER/FDA	1. Tailoring therapies using classification trees 2. Statistical challenges in translating molecular profiling data from preclinical into clinical use as a tailored therapy strategy 3. Discussant
		Hickory/Hawthorne	#3. Biostatistics Researches and Activities at NIH and FDA	Colin O. Wu and Gang Zheng, NIH/NHLBI	Gang Zheng, NIH/NHLBI	1. Ruth Pfeiffer 2. Dean Follmann 3. Nancy Geller 4. Yi Tsong	1. NCI 2. National Institute of Allergy and Infectious diseases 3. National Heart, Lung and Blood Institute 4. FDA	1. Researching, Collaborating and Mentoring: the Roles of Intramural Statisticians at National Cancer Institute 2. Collaborative Statistical Work at NIAID 3. The Evolving Role of Statisticians at NHLBI 4. Leadership Roles of Statisticians at CDER/FDA: From CDER to Pharmaceutical Industry to Professional Society

Laurel Room	#4. Network reconstrcution by high dimensional omics data	Pei Wang, Fred Hutchinson Cancer Research Center	Jie Peng, University of California, Davis	1. Gareth James 2. Li Hsu 3. Pei Wang	1. University of Southern California 2. Fred Hutchinson cancer Research Center 3. Fred Hutchinson Cancer Research Center	1. Sparse Regulation Networks 2. Constructing cancer genetic networks using binary genomic instability data 3. Construct the genetic interaction networks by jointly modeling CGH and expression data
Oak Room	#5. Machine Learning	Tao Shi, Ohio State University	Yoonkyung Lee, Ohio State University	1. Adam Rothma 2. Yoonkyung Lee 3. Guiherme Veiga da Rocha	1. University of Michigan 2. Ohio State University 3. Indiana University	1. Generalized Thresholding of Large Covariance Matrices 2. Functional Component Pursuit 3. Monitoring the Golden Gate Bridge Using Wireless Sensor Networks
Polar Room	#6. Issues in Proof of Concept studies (PoC)	Yin Yin, GSK	Yin Yin, GSK	1. Jiang Lin 2. Yin Yin 3. Shanmei Liao 4. A. Lawrence Gould	1. GSK 2. GSK 3. BMS 4. Merck	1. “Extension of the Bayesian Approach for Sample Size Calculation for a Proof of Concept Study” 2. “Quantification in the Internal Decision Making Process ” 3. “Statistical Challenges in Virology POC design and analysis” 4. Futility Analyses and Proof of Concept Trials
Cypress - 2nd Fl	#7. Statistical Research Stimulated by Medical Studies	Joan X. Hu, Simon Fraser University, Canada	Jason Schroeder, FDA	1. Nan Xue 2. Farouk Nathoo 3. Lang Wu	1. Albert Einstein College of Medicine 2. University of Victoria, Canada 3. University of British Columbia, Canada	1. Estimating the Dose Response Relationship for Occupational Radiation Exposure Measured with Minimum Detection Level 2. Model Adequacy and Kernel Convolution Methods for Multivariate Disease Mapping 3. Joint modelling of longitudinal data and survival data in the presence of missing values and measurement errors

	Cedar - 2nd Fl	#8. Contributed Session I: General Topics		Jiacheng Yuan, Astellas	1. Philip Cheng 2. Olivia Lau 3.Jing Wang 4. Shujie Ma 5. Wheyming Song 6. Hongyuan Cao 7. Jiacheng Yuan	1. Academia Sinica 2. FDA 3. University of Illinois at Chicago 4. Academic 5. Tsing Hua University, Taiwan 6. University of North Carolina 7. Astellas Pharma Global Development, Inc	1. Assessment of DIF for Cognitive Abilities Screening Instrument 2. DIF-Correction and Choosing Survey Vignettes: Examples from the WHO Multi-Country Survey 3. Spline confidence band for strong-mixing sequence 4. A Jump-Detecting Procedure Based on Spline 5. Displaying Meaningful Digits of Statistical Point Estimates 6. Simultaneous Critical Values for t-tests in Very High Dimensions 7. Estimation of Drug Effect and Power Calculation in Crossover Thorough QT Studies
12:15 p.m. - 1:45 p.m.	**1/2 Ballroom - ABWS**	**Round Table Luncheon (Fee Event)**					
2:00 p.m. - 3:40 p.m.	Aspen Room	#9. Analysis of failure time data	Zhezhen Jin, Columbia University	Jason Schroeder, FDA	1. Jane Paik 2. Jianguo Sun 3. Xuewen Lu 4. Joshua Chen	1. Columbia University 2. University of Missouri-Columbia 3. University of Calgary 4. Merck	1. A Class of Semiparametric Models for Spatially Correlated Survival Data 2. University of Missouri-Columbia 3. Asymptotic Distributions of Two Synthetic Data Estimators for Censored Single-Index Models 4. Non-Proportional and Crossing Hazards in Clinical Trials
	Hickory/Hawthorne	#10. Statistical methods for case-cohort studies	Jianwen Cai, University of North Carolina, Chapel Hill	Xiaonan Xue, Albert Einstein College of Medicine	1. Lan Kong 2. Bin Nan 3. Sangwook Kang	1. University of Pittsburgh 2. University of Michigan 3. University of Georgia	1. Linear Regression Analysis of Survival Data from Stratified Case-cohort Studies 2. Case-cohort design versus two-phase sampling 3. Marginal hazard model for case-cohort studies with multiple disease outcomes

Laurel Room	#11. Recent Advances in Optimal Design Theory and Applications in the Biological Sciences	Weng Kee Wong, University of California, Los Angeles	Weng Kee Wong, University of California, Los Angeles	1. Angela Dean 2. Licesio J. Rodríguez-Aragón 3. Weng Kee Wong	1. Ohio State University 2. Universidad de Castilla-La Mancha, Spain 3. University of California, Los Angeles	1. Optimal designs for crossover trials involving interactions between direct and carryover treatment effects 2. Multiplicative algorithm: A method used in optimal experimental design for two factor models 3. A web-based tool for finding optimal experimental designs
Oak Room	#12. Comprehensive Post-Approval Safety Surveillance - Putting All the Pieces Together	Julie Ma and Yi Qian, Amgen	Amy Xia, Amgen and Chien-Feng Chen, Otsuka	1. May Mo 2. Wei Deng 3. Sean Zhao 4. Yi Tsong	1. Amgen 2. Novartis 3. Amgen 4. FDA	1. Meta Analysis of Clinical Trials 2. Statistical Analysis of Safety Data in Pharmacovigilance 3. Observational Studies Based on Large Electronic Health Records and Insurance Claim Data 4. Discussion
Polar Room	#13. Topics in longitudinal data analysis	Jiming Jiang, University of California, Davis	Jimin Ding, Washington University in St. Louis	1. Lan Xue 2. Fang Yao	1. Oregon State University 2. University of Toronto, Canada	1. Incorporating Correlation for Multivariate Failure Time Data When Cluster Size Is Large 2. Modeling Sparse Generalized Longitudinal Observations With Latent Gaussian Processes
Cypress - 2nd Fl	#14. Statistical considerations in non-inferiority trials, including related regulatory guidelines	Julie Ma and Yi Qian, Amgen	Jeetu Ganju, Amgen	1. James Hung 2. Qi Jiang 3. George Chi	1. FDA 2. Amgen 3. Johnson & Johnson	1. Choice of Non-inferiority Margin 2. Toward a consistent standard of evidence when evaluating the efficacy of an experimental treatment from a randomized, active-controlled trial 3. The Roles of Non-inferiority in Clinical Trials
Cottonwood - 2nf Fl	#15. Challenges in Pharmaceutical Statistics	Yonghua Wang, BMS	Ralph Raymond, BMS	1. Dan Anbar 2. Janet Wittes 3. Discussant: Peng-Liang Zhao 4. Discussant: Fanhui Kong	1. DANA Pharmaceutical Consulting 2. Statistics Collaborative, Inc. 3. Sanofi-aventis 4. FDA	1. Regulatory challenges: Subgroup analyses - Must we always adjust for multiplicity? 2. Insinuating Ourselves Early: How Statisticians Can Become Active Participants in Pharmaceutical Development Teams

	Cherry - 2nd Fl (25ppl)	#16. Disease Modification Claim in Neurodegenerative Desease Trials	Kun Jin, FDA	Lu Cui, Eisai	1. Michael P. McDermott 2. Suzanne Hendrix 3. Kun Jin	1. University of Rochester Medical Center 2. Pentara Corporation 3. FDA	1. Issues in the implementation and statistical analysis of two-period designs for demonstrating disease modifying effects 2. Statistical Modeling Approaches to Identifying Disease Modifying Effects 3. On Two-Stage Design for Disease Modifying Claims
	Cedar - 2nd Fl	#17. Contributed Session II: Case Studies		Charity Morgan, University of Alabama at Birmingham	1. Mingchuang Chih and Michael Chuang 2. Yongyi Yu 3. Yi-Chun Chen 4. Balwan Dhillon 5. Yijie Zhou 6. Dr. Ram Janak Yadav 7. Charity Morgan	1. Tsing Hua University, Taiwan and Davis Senior High School 2. Boston Scientific 3. National Tsing Hua University, Taiwan 4. ICMR, Ansari Nagar, New Delhi-29 India 5. Merck 6. NIMS, ICMR, New Delhi-110029, INDIA 7. University of Alabama at Birmingham	1. A case study of a physical examination service in Taiwan 2. Propensity Score Modeling and the Impact on Treatment Effect Evaluation 3. A case study of improving the efficieny of the emergency department 4. Repeat cesarean section versus trail of labor: a comparison of morbidity and mortality at teaching hospitals in India 5. Racial Disparities in Mortality Risks in a Sample of the U.S. Medicare Population 6. Indigenous System of Medicine and Homoeopathy in India 7. Modelling lesion counts data in multiple sclerosis when patients have been selected for baseline activity
3:40 p.m. - 4:00 p.m.	**Ballroom Foyer**	**Break**					
4:00 p.m. - 5:40 p.m.	Aspen Room	#18. QTc assessments in drug development	Julie Ma and Yi Qian, Amgen	Liang Fang, Genentech and Hongjie Deng, (Amgen)	1. Yi Tsong 2. Mike Hale 3. Peng-Liang Zhao	1. FDA 2. Amgen 3. Sanofi-Aventis	1. Assessment of QTc Interval Prolongation Assessment: Comparison of Methods 2. Effective Use of ECG Data in Early Phase Trials 3. Sample size calculation for thorough QTc Study considering bias correction

Hickory/Hawthorne	#19. Incorporating health economic and PRO endpoints in the design and analysis of clinical trials	Julie Ma and Yi Qian, Amgen	Yi Qian, Amgen	1. John Cook 2. Lisa Kammerman 3. Cheryl D. Hill+ , David Macarios*, Yi Qian*, Sacha Satram-Hoang*	1. Merck 2. FDA 3. +RTI Health Solutions, * Amgen Inc.	1. Handling health economic endpoints in multinational clinical trials 2. Review of new FDA PRO guidance 3. Considerations for PROs in Multinational Trials
Laurel Room	#20. Special Invited Session by ASA San Francisco Bay Area Chapter on High Dimensional Data Analysis	John Kornak, President, ASA San Francisco Bay Area Chapter	John Kornak, UCSF	1. Heping Zhang 2. Aiyi Liu 3. Gardar Johannesson 4. John Kornak	1. Yale University 2. NIH 3. Lawrence Livermore National Laboratory 4. UCSF	1. Tree- and forest-based genomic analysis 2. A Rank-Based Test for Comparing Multiple Outcomes 3. BayesLoc: Robust Bayesian Multiple-Earthquake Locator with Application to Aftershocks from the Wenchuan Earthquake 4. Statistical reconstruction of high-noise MRI modalities
Oak Room	#21. Recent advances in small area estimation	En-Tzu Tang, Abbott Laboratories	Irina Udaltsova, University of California, Davis	1. Snigdhansu Chatterjee 2. Huilin Li 3. En-Tzu Tang	1. University of Minnesota 2. NIH/NCI 3. Abbott Laboratories	1. Robust prediction in small area models 2. Adjusted Maximum Likelihood Method: An Application to the Small Area Estimation Problem 3. The best EBLUP in the Fay-Herriot model
Polar Room	#22. Making sense of the human genome: genetic variations underlying complex traits	Hua Tang, Stanford University	I-Ping Tu, Academia Sinica, Taiwan	1. Mingyao Li 2. Xiaofeng Zhu 3. Saunak Sen	1. University of Pennsylvania 2. Case Western Reserve University 3. UCSF	1. Modeling Genetic Inheritance of Copy Number Variations 2. Detecting rare variants for complex traits using linkage and association analysis 3. Selective genotyping and phenotyping in a complex trait context
Cypress - 2nd Fl	#23. Statistical methods for random dynamical systems	Jie Peng, University of California, Davis	Nancy Zhang, Stanford University	1. Giles Hooker 2. Hulin Wu 3. Jie Peng	1. Cornell University 2. University of Rochester 3. University of California, Davis	1. Experimental Design for Nonlinear Stochastic Dynamical Systems 2. Statistical Inference for Random - Coefficient Differential Equation Models with Biomedical Applications 3. Semi-parametric modelling of nonlinear random dynamical systems

Cottonwood - 2nd Fl	#24. Contributed Session III: Extension of Linear Models	Fei Liu, University of Missouri-Columbia	1. Miin-Jye Wen	1. National Cheng-Kung University	1. A General r-way Analysis of Variance Model under heteroscedasticity
			2. Chunling Liu	2. NIH\NICHD	2. Binary regression analysis with a covariate subject to detection limit in a Box-Cox transformation family
			3. Guanghan (Frank) Liu	3. Merck & Co. Inc.	3. Testing and Constructing Confidence Intervals for Proportion Difference in Longitudinal Clinical Trials
			4. Santosh Sutradhar	4. Pfizer Inc	4. A Goodness-of-Fit Test for Overdispersed Binomial Model with Link Functions
			5. Fuxia Cheng	5. Illinois State University	5. Nonparametric Estimation of Error Density in Censored Linear Regression
			6. Harry Khamis	6. Wright State University	6. Testing Proportional Hazards When Covariates are Measured With Error
			7. Fei Liu	7. University of Missouri-Columbia	7. Adaptive Design for Variable Selection
Cedar - 2nd Fl	#25. Contributed Session IV: Joint Modeling	Yuping Zhang, Stanford University	1. Lei Liu	1. University of Virginia	1. Joint Analysis of Multi-level Longitudinal and Survival Data: an Application to the End Stage Renal Disease (ESRD) data
			2. Ali Reza Fotouhi	2. University of the Fraser Valley	2. Joint Modeling in Analysing Clinical Trials Data
			3. Liang Li	3. Cleveland Clinic	3. Semi-parametric Joint Modeling of Longitudinal and Survival Data
			4. Hui Wang	4. UC Berkeley	4. Genetic Association Analysis Using Combined Family Data and Unrelated Cases and Controls
			5. Zhengqing Ouyang	5. Stanford University	5. Modeling gene expression regulation from next generation sequencing
			6. Yuping Zhang	6. Stanford University	6. Modeling longitudinal gene expression for survival analysis

	Cherry - 2nd Fl	#26. Contributed Session V: Mixed Models		Min Tang, University of Maryland, College Park	1. Daoji LI 2. Peng Wang 3. Shubing Wang 4. Jing Qiu 5. Min Tang	1. The University of Manchester, UK 2. Department of Statistics, UIUC 3. Merck Co. & Inc. 4. University of Missouri--Columbia 5. University of Maryland, College Park	1. Empirical likelihood for generalized linear models with longitudinal data 2. Conditional Quadratic Inference Functions for Mixed Effects Models in Longitudinal Data Analysis 3. Weighted Fourier Analysis of Longitudinal Data 4. Statisticsl equivalence test applied to microarray data 5. Goodness of Fit Tests in Linear Mixed Models with One Variance Component
	1/2 Ballroom - ABWS (80ppl)	ICSA and ASA SF Bay Area Joint Career Evening, Co-sponsored by UC Berkeley, Stanford, Cal State East Bay, and UC Davis.	Spring Tseng, Amgen Inc. Haiyan Huang, UC Berkeley		1. Nancy Geller 2. Kathy Harris 3. Kun Jin 4. Ming-Hui Chen	1. NIH and ASA president-elect 2. Amgen, Inc. 3. FDA/CDER 4. University of Connecticut	
7:00 p.m. - 10:00 p.m.							
7:30 a.m. - 10:15 p.m.	**Magnolia Room**	**Symposium Organizing Executive Committee Office**					